C16orf91

Across TCGA pan-cancer cohorts, C16orf91 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated C16orf91 data layer compared with 23 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher C16orf91 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated C16orf91 expression acts as an unfavorable survival marker, although some lineages such as LUAD and COAD show a favorable association.

CCRCC, LUAD, and COAD are the cancer types where C16orf91 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	All	0.710	0.976	.004	27	view →
LUAD	DFS	Tertile	III,IV	0.875	0.150	.006	22	view →
COAD	DFS	Median	II,III,IV	1.000	0.876	.042	12	view →
LSCC	DFS	Tertile	II,III,IV	0.561	0.880	.006	10	view →
HNSC	DFS	Quartile	II,III,IV	0.127	0.739	.038	4	view →
GBM	OS	Tertile	All	0.905	0.718	.034	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

C16orf91–CCRCC (DFS)

Open the CCRCC breakdown →